Antidepressant use during pregnancy
Pro Research Analysisby 
Searched over 200M research papers
Prevalence and Patterns of Antidepressant Use During Pregnancy
Antidepressant use during pregnancy has increased over recent decades, with notable differences across regions. Internationally, about 3% of pregnant women use antidepressants, with higher rates in North America (5.5%) compared to Europe (1.6%) and Australasia (1.3%). Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed, especially sertraline, citalopram, and fluoxetine. The use of these medications has risen over time, reflecting changing prescription practices and healthcare approaches in different countries .
Risks of Antidepressant Use in Pregnancy: Maternal and Fetal Outcomes
Research consistently shows that antidepressant use during pregnancy is associated with some increased risks for both mothers and babies. These include a higher risk of preterm birth, gestational diabetes, abortion, and certain neonatal complications such as low Apgar scores, neonatal adaptation symptoms, and persistent pulmonary hypertension of the newborn. Some studies also report a higher risk of congenital malformations, particularly with paroxetine and fluoxetine, and congenital heart defects with several SSRIs 6710.
However, the absolute risk for most adverse outcomes is small, and the evidence is often complicated by the underlying effects of maternal depression itself. For example, depression during pregnancy—whether treated or untreated—is linked to increased risks of low birth weight, preterm birth, and other complications. When comparing women with depression who use antidepressants to those who do not, the main additional risks are preterm birth and neonatal intensive care unit (NICU) admission 610.
Balancing Benefits and Risks: The Importance of Treating Maternal Depression
Untreated depression and anxiety during pregnancy can have serious negative effects on both the mother and the developing child, including increased risk of postpartum depression, poor self-care, and negative impacts on child development. For women with severe depression, the benefits of antidepressant treatment often outweigh the potential risks, as untreated mental illness can be more harmful than the medication itself 2359.
Most guidelines recommend psychotherapy as the first-line treatment for mild to moderate depression during pregnancy, reserving antidepressants for more severe or recurrent cases. When medication is necessary, careful selection of the drug (avoiding those with higher risk profiles like paroxetine and fluoxetine) and close monitoring are advised 279.
Patient and Provider Perspectives: Decision-Making Challenges
Both patients and healthcare providers often feel uncertain about the safety of antidepressant use during pregnancy, leading to inconsistent decision-making and distress for pregnant women. Patients frequently report dissatisfaction with the information provided and feel unsupported in making these complex decisions. Providers may lack up-to-date training or confidence in counseling about perinatal psychopharmacology. Improved knowledge translation, better communication, and shared decision-making tools are needed to support informed choices 48.
Conclusion
Antidepressant use during pregnancy is a complex issue with both potential risks and important benefits. While there is a small increased risk of certain adverse outcomes, untreated depression also poses significant dangers. Decisions about antidepressant use should be individualized, weighing the severity of maternal illness against the specific risks of medication, and should involve clear communication and support from healthcare providers. Ongoing research and improved education for both patients and clinicians are essential to guide safe and effective care during pregnancy 1234+6 MORE.
Sources and full results
Most relevant research papers on this topic